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Abstract 
Importance: Traditionally, elevated troponin concentrations were synonymous with myocardial 
infarction. However, with improvements in troponin assays, elevated concentrations without 
overt myocardial ischemia is now more common; an entity referred to as myocardial injury. 
Physicians may be falsely reassured by the absence of myocardial ischemia; however, recent 
evidence suggests that myocardial injury is associated with even more detrimental outcomes. 
Accordingly, we review the definition, epidemiology, differential diagnosis, diagnostic 
evaluation, and management of myocardial injury. 
Observations: Contemporary epidemiological evidence suggests that myocardial injury (without 
overt ischemia) represents ~60% of cases of abnormal troponin concentrations when obtained for 
clinical indications. It is estimated that 1 in 8 patients presenting to the hospital will have 
evidence of myocardial injury. Myocardial injury pertains a concerning prognosis; 5-year 
mortality is ~70%, with a major adverse cardiac event rate of 30% over the same period. The 
differential diagnosis for myocardial injury is broad and can be divided into acute and chronic 
precipitants. The initial work-up involves an assessment for myocardial ischemia. If infarction is 
ruled out, further evaluation includes a detailed history, physical examination, laboratory 
testing,12-lead electrocardiogram, and if there is no known history of structural or valvular heart 
disease, an echocardiogram. Unfortunately, no consensus exists regarding routine management 
of patients with myocardial injury. Identifying and treating the underlying precipitant is the most 
practical approach.  
Conclusion and Relevance: Myocardial injury is the most common etiology for abnormal 
troponin results, and its incidence will likely increase with an aging population, increasing 
prevalence of cardiovascular comorbidities, and greater sensitivity of troponin assays. 
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Myocardial injury represents a challenge to clinicians, however given its serious prognosis, it 
warrants a thorough evaluation for its underlying precipitant. Future strategies to prevent and/or 
manage myocardial injury are needed.  
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Introduction 
Cardiac troponin (cTn) was first discovered as a component of the myofibrillar apparatus in 
1963.1 It was, however, a further 30 years before a reliable serum assay for cTn measurement 
was developed. cTn assays were developed and validated to diagnose acute myocardial 
infarction (MI) and shown to detect MI with greater accuracy than creatine kinase because of 
their improved analytical performance, superior analytical sensitivity, and tissue specificity.2 The 
majority of cTn in the cardiac myocyte is bound within the sarcomere, while ~5% remains free 
in the cytoplasm.3 It is thought that under ischemic conditions, when MI occurs, free cytoplasmic 
cTn is released first causing an initial rapid change in cTn concentration, while myofibrils are 
subsequently degraded over several days resulting in a more stable and continuous cTn release.3 
With improvements in technology, cTn can now be quantified above the limit of detection in 
≥50% of healthy individuals using high-sensitivity (hs) cTn assays;4 some pre-clinical assays 
may reliably detect concentration of cTn in all normal subjects. The mechanism of cTn detection 
in healthy individuals is not fully understood but hypothesized to be related to myocyte 
turnover.5 These advancements in analytical sensitivity have facilitated the early, rapid rule-in 
and rule-out of MI with ensuing potential to improve patient outcomes and decrease healthcare 
costs.6  
 The improved analytical sensitivity and the use of the 99th percentile upper-reference 
limit (URL) as the preferred concentration threshold for detecting myocardial injury, however, 
comes with challenges including increased recognition of cTn concentrations >99th percentile 
without overt myocardial ischemia.7 This circumstance, termed myocardial injury, is now 
acknowledged in the Fourth Universal Definition of MI as a separate entity.8 Several studies 
indicate that using contemporary and hs-assays, myocardial injury in the absence of ischemia is 
 6 
the most common cause of an increased cTn.9,10 Accustomed to the connotations that a diagnosis 
of MI carries, physicians may be falsely reassured by the absence of MI. Myocardial injury, 
however, is associated with even worse outcomes, with 5-year mortality rates and major adverse 
cardiovascular events (MACE) of ~70% and ~30% respectively over the same period.11 Notably, 
patients with myocardial injury without evidence of infarction, may not necessarily derive 
benefit from traditional therapies for ischemia.12,13 
 Myocardial injury may be conceptually challenging and its evaluation difficult. While the 
term myocardial injury applies to any patient with an increased cTn >99th percentile (including 
those with MI), the term is now endorsed as the preferred nomenclature to refer to patients with 
isolated cTn increases without MI. In this article, the definition, epidemiology, differential 
diagnosis, and prognosis of myocardial injury are reviewed, after which we provide a practical 
approach to its evaluation and management.  
 
Defining Myocardial Injury 
Myocardial injury is defined as any cTn concentration above the 99th percentile URL.8,14 
Myocardial injury is considered acute if there is a rise and/or fall of cTn concentrations 
exceeding biological and/or analytical variation.15 No standard exists for how much rise and/or 
fall of hs-cTn identifies acute injury; typically an increase in the cTn concentration greater than 
the reference change value (biological variation of an assay) is considered acute for both cTnT 
and cTnI assays if the initial cTn value is < 99th percentile.14 If the first cTn level is > 99th 
percentile then an increase of at least 50% of the 99th percentile or a change > 20% may be 
considered acute.14 While small changes in cTn concentration have poor specificity, a large rise 
and/or fall is much more specific for acute myocardial injury with the largest increases typically 
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occurring in acute MI (Figure 1); the larger the rise and/or fall of cTn, the higher the positive 
predictive value for MI.15 
 To diagnose any of the five types of MI (Table 1), in addition to acute myocardial injury, 
there must be clinical evidence of acute myocardial ischemia. The diagnosis of myocardial 
ischemia requires at least one of the following: 1) symptoms of myocardial ischemia, 2) new 
ischemic electrocardiographic changes, 3) new ischemic regional wall motion abnormalities on 
cardiac imaging, or 4) acute coronary thrombus on coronary angiography.8 In the absence of 
these pre-requisites, MI cannot be diagnosed. Differentiating type 2 MI from myocardial injury 
can be particularly challenging. Both entities can have overlapping precipitants [e.g. heart failure 
(HF) and sepsis] but they are differentiated by the presence of ischemia which is needed to 
diagnose type 2 MI.8 However, evaluating for the presence of ischemia can be challenging in 
certain situations such as the intubated patient or when atypical symptoms exist. 
 At lower cTn concentrations, which are the most often frequently encountered in clinical 
practice; besides ischemic mechanisms leading to acute MI, several other mechanisms of acute 
myocardial injury have been described, including those that cause increase cTn release such as 
myocardial strain,16 inflammation,17 apoptosis,16 and cell injury,18 or those that decrease cTn 
clearance such as acute or chronic kidney injury (Figure 2);19 all must be considered in the 
differential diagnosis if the presentation is ambiguous.  
 A cTn result above the 99th percentile URL without a rise and/or fall over a period of 
serial measurements (e.g. over 8 hours) is characteristic of chronic myocardial injury in the 
appropriate clinical setting.  
   
Epidemiology 
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The reported incidence of myocardial injury has varied according to the setting in which the cTn 
was measured (Table 2). In a cohort of 918 consecutive patients presenting to the emergency 
department (ED) without symptoms of MI, the incidence of myocardial injury was 12% (of 
which 4% of patients were had MI).20 Predictably, among patients presenting to the ED with 
suspicion of MI the incidence of myocardial injury is higher. In the Use of TROPonin In Acute 
coronary syndrome (UTROPIA) study, a prospective observational study of 1,640 ED patients 
undergoing serial hs-cTnI (Abbott) measurements on clinical indication, Sandoval and 
colleagues found that 26% of patients had at least one cTnI >99th percentile, of which 58% were 
determined to be myocardial injury.9 The investigators found that the most frequent etiologies of 
myocardial injury were renal failure, HF, and neurological conditions.9 The High-Sensitivity 
Troponin in the Evaluation of patients with suspected Acute Coronary Syndrome (High-
STEACS) trial was a stepped-wedge, cluster-randomized controlled trial that prospectively 
evaluated the implementation of a hs-cTnI assay among 48,282 consecutive patients presenting 
with suspected MI to ten hospitals in Scotland.21 The investigators found the incidence of 
myocardial injury to be 21%, of which 69% were diagnosed with MI. Notably, few 
epidemiological studies to date have differentiated acute from chronic myocardial injury. 
Examining 39,558 patients presenting to the ED with chest pain, Kadesjo and colleagues found 
that 3,855 patients had a hs-cTn concentration greater than the 99th percentile. Of these, 29% had 
type 1 MI, 6.5% had type 2 MI, 29.5% had acute myocardial injury, and the majority (35%) had 
chronic myocardial injury.22 
 In the current era of hs-assays, myocardial injury may now be the most common cause of 
increased cTn when examined in hospitalized patients. Using the Veterans Affairs centralized 
databases, McFalls et al. identified patients hospitalized with increased cTn concentrations in 
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2006.10 Among 100, 433 patients who had a troponin (cTnT or cTnI) measured during their 
index admission, 24% were diagnosed with myocardial injury; the majority (57%) were not 
found to have MI.10 Of the patients with non-infarction cTn increases, more than 40% carried a 
primary diagnosis of cardiac origin, such as HF and chronic coronary artery disease (CAD), 
while others were diagnosed with infections or diseases related to the renal, gastrointestinal, and 
neurologic systems.10 Similarly, examining 3,762 patients with hs-cTnI measured during index 
hospitalization, Sarkisian et al. found the incidence of myocardial injury to be 42% and only 
31% of these patients were diagnosed with MI.23 Dolci et al. found the incidence of ischemic and 
non-ischemic myocardial injury among hospitalized patients to be slightly higher at 59%.24   
 
Differential Diagnosis 
The differential diagnosis for myocardial injury is broad and can be divided into acute or chronic 
causes (Figures 1 and 2).  
Acute Myocardial Injury 
When a rise and/or fall of cTn with at least one concentration >99th percentile URL is 
encountered, acute MI is a primary consideration; the larger the magnitude of the cTn increase, 
the more likely acute MI is the cause. That said, even when faced with moderate degrees of 
injury, a broad range of precipitants of myocardial injury should be considered. Cardiovascular 
causes of acute myocardial injury include MI,8 pulmonary embolism (PE),25 myocarditis,17 
and/or myopericarditis,26 aortic dissection,27 cardiac surgery,28 or procedures29 (e.g. 
cardioversion or ablation), hypertension,16 arrhythmias,30 acute HF,31 acute valvular heart 
disease32 (e.g.: aortic regurgitation or mitral regurgitation), Takotsubo cardiomyopathy,33 and 
cardiac contusions34 (including chest compressions). If accompanying clinical evidence of acute 
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myocardial ischemia is identified, then acute MI should be diagnosed. For example, in the 
absence of overt myocardial ischemia, most patients with acute HF should be categorized as 
having myocardial injury; however, acute HF can occur due to myocardial ischemia, and when 
these patients are identified to have clinical evidence of myocardial ischemia, then acute MI is 
diagnosed. Non-cardiovascular causes and/or triggers of myocardial injury include acute renal 
failure,35 sepsis,36 anemia,37 hypotension,38 hypoxia,39 non-cardiac surgery,40 critical illness,41 
rhabdomyolysis,42 drug induced (e.g. chemotherapy),18 stroke,43 and extreme exertion.44 A 
common vexing issue is the effect of renal dysfunction on cTn concentrations. One prevalent 
hypothesis is that myocardial injury in patients with advanced kidney disease is a consequence of 
decreased clearance of cardiac troponin. However, its presence is likely multifactorial and also 
influenced by other factors such as underlying CAD,45 and left ventricular mass.19 
Chronic Myocardial Injury 
Cardiovascular causes of chronic myocardial injury include chronic HF,46 infiltrative 
cardiomyopathies47 (amyloidosis, hemochromatosis, and sarcoidosis), hypertrophic 
cardiomyopathy,48 stable CAD,49 hypertension,50 valvular heart disease,51 and persistent 
arrhythmias (e.g. atrial fibrillation).52 Non-cardiovascular causes include chronic renal disease,53 
pulmonary hypertension,54 toxins,55 and diabetes mellitus.56 
 
Prognosis 
Emerging evidence from several observational studies indicates that myocardial injury pertains a 
concerning prognosis (Figure 3). Most studies have not delineated acute versus chronic 
myocardial injury without infarction, and there remains limited data on differences in outcomes 
between these two entities.  
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 One small retrospective study showed that patients with non-cardiac precipitating factors 
for their increased cTnI at presentation have higher in-hospital mortality (26.7% vs. 13.4%, 
p=0.002) compared to cardiac-related precipitants.57 Beyond the initial hospitalization, 
myocardial injury has high short term mortality; 11% at 6 months and 26% at 2-years.9 Age, 
maximum cTnI concentration, and a history of HF were predictive of 2-year mortality.9 Longer 
term outcomes were examined by Chapman and colleagues, who found that 5-year mortality was 
as high as 72%.11 The long-term mortality from myocardial injury was mostly driven from non-
cardiovascular causes (62%).11 Accordingly, some of this mortality risk may not be modifiable. 
Cardiovascular event rates, however, are also high among this population. The 5-year MACE 
rates were 31% with 28% of patients experiencing a cardiovascular death.11 Over 5-years, 4.8% 
of patients with myocardial injury experience a non-fatal MI, 5.6% a HF hospitalization, and 
3.9% a stroke.11 Patients with myocardial injury in the absence of MI, had a higher risk of all-
cause mortality compared to type 1 MI (adjusted relative risk: 2.09; 95% confidence interval, 
1.72-2.55) but a lower risk of MACE (adjusted relative risk 0.77 95% confidence interval, 0.66-
0.89). A large retrospective analysis of 9,800 patients with myocardial injury without MI, 
diagnosed by either conventional or hs-cTn, included in the SWEDEHEART registry (Swedish 
Web-system for Enhancement and Development of Evidence-based care in Heart disease 
Evaluated According to Recommended Therapies) found similarly morbid long term outcomes; 
with 15.4% of patients having MACE (composite of all-cause mortality, MI, readmission for HF, 
or stroke at a median follow-up 4.9 years). Furthermore, they reported that the magnitude of 
myocardial injury was an important predictor of mortality, with successive increases in hazard 
ratios across troponin tertiles, even when adjusting for presence of cardiovascular disease or 
prevalent comorbidities.58 Examining outcomes among patients with myocardial injury 
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diagnosed in the ED, Kadesjo et al. found that patients with acute myocardial injury had a 21% 
higher risk of all-cause mortality and a 30% higher risk of HF compared to patients with chronic 
myocardial injury over a median follow-up of 3.9 years.22  
Myocardial injury occurs in a heterogeneous group of patients; consisting of both cardiac 
and non-cardiac types of insult; which likely confer different prognostic implications. A 
prospective study on patients with myocardial injury categorized patients based on etiology: 
ischemic, non-ischemic cardiac (e.g. major cardiac surgery), noncardiac (e.g. infection) or 
multifactorial (at least 2 cardiac or non-cardiac conditions) conditions.59 Researchers found that 
after adjusting for covariates, cardiac ischemic and non-ischemic patients had similar mortality 
rates. However, diagnoses of noncardiac and multifactorial causes of myocardial injury carried 
higher mortality compared to cardiac ischemic types of injury (hazard ratio 1.39, 95% 
confidence interval 1.06-1.80; p =0 .02).59 Patients with chronic HF often have evidence of 
myocardial injury and a meta-analysis of 9,289 patients found that cTn increases predicted all-
cause mortality (hazard ratio (HR) 1.48, p<0.001), cardiovascular death (HR 1.40, p<0.001), and 
cardiovascular hospitalization (HR 1.42, p<0.001).46  
Troponin levels may correlate with clinical prognosis in some cases. Increases in cTnI 
concentrations in patients undergoing high dose chemotherapy for aggressive malignancies have 
been correlated with future reductions in left ventricular ejection fraction.60 In patients with 
chronic kidney disease and end-stage renal disease, increased cTn concentrations are associated 
with higher rates of all-cause mortality.61,62 In patients with amyloidosis47 or pulmonary 
embolism,63 detection of cTn were found to be strong predictors of all-cause mortality. Troponin 
detection can also be induced by exercise, though the clinical implication of the cTn elevation 
not well understood.44 Prognostication using cTn certainly does not apply for all causes of 
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myocardial injury nor would peak cTn level necessarily enable prognostication across various 
causes of myocardial injury, which can cause vastly different levels of cTn elevation. 
Risk stratification for patients with myocardial injury and identification of patients would 
benefit from close monitoring and further testing is an area of ongoing investigation, especially 
given the evidence that increased cTn concentrations carry prognostic significance. Risk 
stratification may guide frequency of follow-up visits post-discharge facilitating surveillance for 
symptoms of ischemia, HF, and optimization of preventative therapies. The TARRACO 
(Troponin Assessment for Risk stRatification of patients without Acute COronary athero-
thrombosis) risk score was recently developed to risk stratify patients with type 2 MI or 
myocardial injury and externally validated in a cohort of 401 patients.64 The score combines 
incorporates cTn concentrations and predictors of adverse cardiovascular events in this 
population, including age, hypertension, absence of chest pain, dyspnea, and anemia. MACE 
events were five times higher in the high-risk patients compared to the lowest risk patients based 
on this score.64 The utility of this score to alter the prognosis of patients (by guiding further 
investigation or therapeutic intervention) will however need evaluation in a clinical trial.  
Taken together, these trends in morbidity and mortality underscore the reality that 
myocardial injury with ‘negative’ ischemic work-up does not offer reassurance; rather, a careful 
evaluation for alternate etiologies should be considered. Furthermore, trivializing such 
circumstances as a "troponin leak" or "troponinemia" is strongly discouraged. Although 
prospective studies are needed to demonstrate that outcomes for patients with myocardial injury 
are indeed modifiable, the consistency of the evidence that myocardial injury is associated with 
very poor outcomes across a broad range of healthcare settings requires clinicians to take 
elevated troponin seriously.    
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Evaluating Myocardial Injury 
The initial assessment of myocardial injury focuses on the 1) assessment of ischemic symptoms, 
2) review of the patients past medical history and cardiovascular risk factors, 3) serial 12-lead 
electrocardiograms, 4) serial cTn measurements assessed over 3-12 hour periods depending on 
sensitivity of the assay, 5) imaging: an echocardiogram to assess for regional wall motion 
abnormalities and exclude the presence of cardiomyopathy and/or structural heart disease, and/or 
6) coronary angiography (computerized tomography or invasive).  
 If the patient reports symptoms of angina—even atypical—they nominally meet the 
Universal Definition for acute MI, and an ischemic evaluation should be undertaken, if not 
previously performed. If myocardial infarction is excluded the subsequent assessment includes a 
comprehensive history and physical examination, laboratory testing, and where appropriate, 
cardiac imaging. 
History and Physical Examination 
Inquiring about the presence and nature of chest discomfort is important. Pleuritic discomfort 
may suggest PE, pneumonia, or myocarditis. Discomfort radiating to the back may suggest aortic 
dissection. Symptoms suggestive of HF (dyspnea, orthopnea, paroxysmal nocturnal dyspnea, and 
peripheral edema), valvular heart disease (syncope, angina, and dyspnea), cardiac arrhythmias 
(palpitations), and infections (fevers, chills) should be explored. Recent procedures (cardiac and 
non-cardiac), use of cardiotoxic medications (in particular chemotherapy and substance abuse), 
activity (intense exercise regimens), life stressors (Takotsubo cardiomyopathy), recent travel, 
and past medical history (specifically cardiovascular, pulmonary, and renal comorbidities) 
should be reviewed.   
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 The physical examination must include an appraisal of the patients’ vital signs, 
cardiovascular system (heart rate and rhythm, murmurs, presence of congestion), pulmonary 
system (wheezing, rhonchi, and crackles), and potential sources of infection.  
Laboratory Data and Imaging 
Serial cTn measurements are informative to differentiate acute from chronic myocardial injury; 
when using hs-cTn assays. In early and late presenters or in those in whom symptom onset is 
uncertain and distinguishing acute vs. chronic injury from infarction remains uncertain, a 3rd 
sample can be helpful as up to 26% of patients with acute MI may not demonstrate a significant 
rise and/or fall.65 A 12-lead electrocardiogram should be obtained at presentation and reviewed 
for signs of ischemia/infarction, arrhythmias, acute right ventricular strain, and signs of 
conduction or structural disease (e.g. left ventricular hypertrophy). We recommend assessment of 
renal function and measurement of a natriuretic peptide to provide complementary information 
regarding common causes of non-MI related injury, such as chronic kidney disease or HF, 
respectively). A complete blood count (anemia or infection) should be attained. Additional 
laboratory testing such as d-dimer (considering PE and aortic dissection), and 
infectious/inflammatory markers (e.g. c-reactive protein) can be guided by clinical assessment. 
An echocardiogram should be obtained to assess for systolic or diastolic dysfunction, left 
ventricular hypertrophy, wall motion abnormalities, or valvular abnormalities. Further imaging 
such as cardiac magnetic resonance imaging may be obtained depending on the clinical scenario 
(e.g. suspected myocarditis or infiltrative cardiomyopathy).  
 
Treatment 
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For type 1 MI, an evidence-based treatment is well established.66,67 For type 2 MI, present 
recommendations are to individualize care and correct the supply/demand alteration (e.g.: 
anemia, tachycardia, hypotension, etc.) leading to myocardial ischemia. The DEtermining the 
Mechanism of myocardial injury AND role of coronary disease in type 2 Myocardial Infarction 
(DEMAND MI; NCT03338504) trial is attempting to improve our understanding of the 
mechanisms of ischemic myocardial injury by engaging computed tomography coronary 
angiography, invasive coronary angiography, and cardiac magnetic resonance imaging. The 
Appropriateness of Coronary investigation in myocardial injury and Type 2 myocardial 
infarction (ACT-2) trial is randomizing 300 patients with myocardial injury to invasive 
angiography (or computed tomography angiography) within 5 days of randomization versus 
conservative management (with or without functional testing at clinician discretion) with a 
primary endpoint of all-cause mortality at 2 years.68 Cost-effectiveness will be determined based 
on clinical events, quality of life, and resource utilization over 24 months.68 
 Beyond those patients with ischemic myocardial injury, unfortunately, no consensus 
exists regarding routine management of patients with myocardial injury. The management of 
myocardial injury may thus focus on the identification and treatment of the underlying 
precipitant (e.g. HF).  
 Whether therapies to attenuate injury itself are of benefit remains unclear and data are 
largely retrospective and/or inconclusive. The WOSCOPS (West of Scotland Coronary 
Prevention Study) investigators found pravastatin reduced hs-cTnI concentrations in an 
ambulatory population free of prior MI by an average of 13%, and change in troponin at 1-
year was associated with future MI risk reduction independent of cholesterol lowering.69 
However, this was a primary prevention study, and the applicability of these findings to patients 
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with acute non-ischemic myocardial injury is uncertain. The MANAGE (Management of 
Myocardial Injury After Noncardiac Surgery) trial found that dabigatran lowered major vascular 
event rates when compared with placebo (11% versus 15%, p=0.02) among patients with 
myocardial injury after noncardiac surgery.70 Nonetheless, the results of this trial should be 
interpreted cautiously as the trial was terminated early and medication discontinuation rates were 
high. Further, given the heterogeneity in etiologies, it is difficult to conceive that one-single 
approach can be used for all patients and the primary composite endpoint was broad (vascular 
mortality, non-fatal MI, non-hemorrhagic stroke, peripheral arterial thrombosis, amputation, and 
symptomatic venous thromboembolism). Lastly, sodium-glucose cotransporter 2 inhibitors 
(SGLT2i) have been shown to enhance diuresis, reduce blood pressure, and improve left 
ventricular remodeling.71 In patients with diabetes mellitus, canagliflozin delayed a rise in 
troponin over 2-years when compared to placebo.72 Thus, these agents, along with others with 
alter hemodynamic stress, warrant investigation among patients with myocardial injury.   
 
Conclusion 
The 4th Universal Definition of MI recently considered the phenomenon of myocardial injury as 
a separate, unique entity. Myocardial injury is the most common etiology for abnormal hs-cTn 
results, and its incidence will likely increase with an aging population, increasing prevalence of 
cardiovascular comorbidities, and greater sensitivity of hs-cTn assays. Myocardial injury 
represents a challenge to clinicians, however given its serious prognosis, it warrants a thorough 
evaluation for its underlying precipitant. Future strategies to prevent and/or manage myocardial 
injury are needed.  
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Figure Legends 
Figure 1: Figure illustrating most likely causes of myocardial injury stratified by cardiac 
troponin concentration. Abbreviations: HF= heart failure, LVH= left ventricular hypertrophy, 
MI= myocardial infarction, PE= pulmonary embolism. Taken with permission from Januzzi JL 
Jr et al; Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing: 
JACC Scientific Expert Panel. JACC:2019;73(9):1059-1077. 
 
Figure 2: Figure illustrating the evaluation, differential diagnosis, and approach to management 
of acute and chronic myocardial injury. Abbreviations: ECG= electrocardiogram, PCI= 
percutaneous coronary intervention, TTE= transthoracic echocardiogram.  
 
Figure 3: Multivariable-adjusted hazard ratios (with 95% CIs) of major adverse events in 
patients with troponin elevation without specific diagnosis and in subcohorts. In all cohorts, the 
risk of major adverse events increased in a stepwise fashion across higher assay-specific cardiac 
troponin (cTn) levels, with patients in the highest tertile being at particularly high risk. Patients 
with cTn ≤99th percentile were used as reference group. All analyses are adjusted for age, sex, 
admission year, hospital, and cTn assay. CABG = coronary artery bypass grafting; 
CI = confidence interval; cTn = cardiac troponin; eGFR = estimated glomerular filtration rate; 
HR = hazard ratio; LVEF = left ventricular ejection fraction; MI = myocardial infarction; 
PCI = percutaneous coronary intervention. Taken with permission from Eggers et al; Cardiac 
troponin Elevation in Patients Without Specific Diagnosis. JACC:2019;73:1-9.  
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Table 1: Definitions of Acute and Chronic Myocardial Injury and the Subtypes of Myocardial 
Infarction 
Myocardial Injury Troponin concentration above the 99th percentile URL, regardless of cause  
 Acute Dynamic rise and/or fall of troponin concentration due to cardiovascular or 
non-cardiovascular causes  
 Chronic Persistently elevated troponin concentration due to cardiovascular or non-
cardiovascular causes 
Myocardial 
Infarction 
Dynamic rise or fall of troponin concentration above 99th percentile URL with 
myocardial ischemia evidenced by 1) symptoms of ischemia, 2) new ischemic 
electrocardiographic findings, 3) new ischemic wall motion abnormalities on 
echocardiogram, 4) coronary thrombus visualized on coronary angiography 
 Type 1 Myocardial infarction caused by plaque rupture, ulceration, or dissection 
 Type 2 Myocardial infarction due to oxygen supply-demand mismatch  
 Type 3 Sudden cardiac death with etiology most likely myocardial infarction  
 Type 4 Myocardial infarction associated with percutaneous intervention or stent 
thrombosis  
 Type 5 Myocardial infarction associated with cardiac surgery 
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Table 2: Table showing studies which report detection of myocardial injury in various settings. 
Abbreviations: ACS=acute coronary syndrome, cTn= cardiac troponin, ED= emergency 
department, hs-cTn=high sensitivity troponin, MI=myocardial infarction, VA=veterans affairs. 
Study Setting Location Assay Incidence of 
Myocardial 
injury  
Cause of 
myocardial injury  
Reference 
Lee et al.  918 consecutive 
patients 
presenting to the 
ED without 
symptoms of ACS 
Scotland Hs-cTnI 
(Abbott) 
12% - Non-ischemic 
myocardial injury= 
96%. 
 
- MI= 4%.  
 
20 
Sandoval et 
al. 
1,640 patients 
presenting to the 
ED for suspicion 
of ACS 
United 
States  
Hs-cTnI 
(Abbott) 
26% - Non-ischemic 
myocardial injury= 
58% 
 
- MI= 42% 
 
9 
Shah et al. 48,282 patients 
presenting to the 
ED for suspicion 
of ACS 
Scotland Hs-cTnI 
(Abbott) 
21% - Non-ischemic 
myocardial injury= 
31% 
 
- MI= 69% 
 
21 
Kadesjo et 
al.  
39,558 patients 
presenting to the 
ED for suspicion 
of ACS 
Sweden Hs-cTnT  10% - Non-ischemic 
myocardial injury 
64.5% (29.5% acute 
injury and 35% 
chronic injury) 
 
- MI= 35.5% 
 
22 
Sarkisian et 
al. 
3,762 patients 
with hs-cTn 
measured during 
Denmark Hs-cTnI 
(Abbott) 
42% - Non-ischemic 
myocardial injury= 
69% 
23 
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their 
hospitalization. 
 
- MI= 31% 
 
Dolci et al.  1,137 patients 
with hs-cTn 
measured during 
their 
hospitalization. 
Italy Hs-cTnT 
(Roche). 
59% Not provided 24 
McFall et al.  100, 433 VA 
patients with cTn 
measured during 
their index 
admission 
United 
States 
cTnI and 
cTnT 
24% - Non-ischemic 
myocardial injury= 
57% 
 
- MI= 43% 
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